Vancouver, Canada – April 8, 2026 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced it will attend and present new data at the British Society for Rheumatology (BSR) 2026 Annual Meeting, taking place April 28–30 in Glasgow, UK.
At BSR 2026, Augurex will showcase its biomarker-driven diagnostic portfolio supporting earlier and more informed care decisions in inflammatory arthritis, including:
- JOINTstat® (14-3-3eta): for the diagnosis, prognosis, and monitoring of rheumatoid arthritis (RA).
- SPINEstat® (Anti-14-3-3eta Multiplex): a first-in-class diagnostic designed to aid in the identification of axial spondyloarthritis (axSpA).
Augurex will present three scientific posters spanning both RA and axSpA:
Poster Presentations:
-
- Validation of a 14-3-3eta Autoantibody Assay Combined with CRP and HLA-B27 to Improve Axial Spondyloarthritis Detection
Poster number: P023 📅 April 28 | 🕒 10:30 AM – 11:10 AM
- Validation of a 14-3-3eta Autoantibody Assay Combined with CRP and HLA-B27 to Improve Axial Spondyloarthritis Detection
-
- Autoantibodies to 14-3-3η: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Poster number: P024 📅 April 28 | 🕒 10:30 AM – 11:10 AM
- Autoantibodies to 14-3-3η: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
-
- High Specificity and Diagnostic Utility of Serum 14-3-3η in Rheumatoid Arthritis: Evidence from a Clinically Diverse Cohort
Poster number: P120 📅 April 28 | 🕒 3:15 PM – 3:55 PM
- High Specificity and Diagnostic Utility of Serum 14-3-3η in Rheumatoid Arthritis: Evidence from a Clinically Diverse Cohort
The axSpA data further support the clinical utility of the novel Anti-14-3-3eta Multiplex biomarker (SPINEstat®) in enabling earlier and more accurate detection of axSpA, improving differentiation from mechanical back pain, and complementing established markers such as CRP and HLA-B27. Together, these findings reinforce the role of biomarker-based approaches in addressing long-standing diagnostic delays in inflammatory back disease.
The RA data demonstrate the high specificity and diagnostic utility of serum 14-3-3eta across a clinically diverse cohort, further supporting its value in improving diagnostic confidence and risk stratification in rheumatoid arthritis.
Augurex looks forward to engaging with rheumatology clinicians, researchers, and partners at BSR 2026 to discuss ongoing research and collaborative opportunities.
For more information or to schedule a meeting with our team during the conference, please reach out to nmazinani@augurex.com.
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s 14-3-3eta blood test, available as JOINTstat® in Canada and in Great Britain, is an important tool in the diagnosis and management of rheumatoid arthritis. Analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex test, approved as SPINEstat® in Canada and Great Britain, expands Augurex’s portfolio of autoimmune diagnostic solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.